RxDoctor Payments Data

Marla Moses

Family · Indianapolis, INNPI 1740431154

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $127,413 of the $142,201 with a category attached, or 89.6%. AbbVie accounts for 96.3% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $52,026, more than ten times the $4,642 reported in 2021. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$142,201in general payments, 2019–2025

Across 509 payments — averaging $279.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$137K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Sunovion Pharmaceuticals Inc.$1K
  • Alkermes, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$946
  • Supernus Pharmaceuticals, Inc.$333
  • plus $651 from 6 others

What the payments were for

  • Speaking & faculty fees$127,41390%
  • Travel & lodging$6,2044%
  • Food & beverage$8,5306%
  • Education$540%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$142,201 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$47,025
VraylarCariprazine Hcl12$17,454
Adderall XrDextroamphetamine/Amphetamine17$7,512
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine59$5,879
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine38$1,618
Aripiprazole15$1,474
Lansoprazole16$699
Quetiapine Fumarate ErQuetiapine Fumarate26$682
Clonazepam46$594
Duloxetine Hcl23$311
Promethazine Hcl17$294
Zolpidem Tartrate16$228
Lithium Carbonate ErLithium Carbonate22$225
Lamotrigine34$174
Diazepam12$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$42$47,02513 claims
AbbVieVraylar$136,956$17,45412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →